EDIT - Editas Medicine beats top and bottom line estimates
2023-11-03 07:03:16 ET
More on Editas Medicine
- Editas Medicine: A Mispriced Contender In The Gene Editing Arena
- Editas Medicine: RUBY Gems, Sparkling Catalysts In Sickle Cell Arena
- Editas Medicine, Inc. (EDIT) Cantor Global Healthcare Conference 2023 - (Transcript)
- Editas Medicine Q3 2023 Earnings Preview
- Editas upgraded at Citi ahead of FDA AdCom on gene editing therapy
For further details see:
Editas Medicine beats top and bottom line estimates